Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 1
2021 1
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean zhao jie min (10 results)?
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.
Feagan BG, Sands BE, Sandborn WJ, Germinaro M, Vetter M, Shao J, Sheng S, Johanns J, Panés J; VEGA Study Group. Feagan BG, et al. Among authors: shao j. Lancet Gastroenterol Hepatol. 2023 Apr;8(4):307-320. doi: 10.1016/S2468-1253(22)00427-7. Epub 2023 Feb 1. Lancet Gastroenterol Hepatol. 2023. PMID: 36738762 Clinical Trial.
Of the 214 patients included, 98 (46%) were women and 116 (54%) were men and the mean age was 38.4 years (SD 12.0). At week 12, 59 (83%) of 71 patients in the combination therapy group had achieved clinical response compared with 44 (61%) of 72 patients in the golimumab mo …
Of the 214 patients included, 98 (46%) were women and 116 (54%) were men and the mean age was 38.4 years (SD 12.0). At week 12, 59 (8 …
A Clinical Practice Guideline for the Emergency Management of Anaphylaxis (2020).
Li X, Ma Q, Yin J, Zheng Y, Chen R, Chen Y, Li T, Wang Y, Yang K, Zhang H, Tang Y, Chen Y, Dong H, Gu Q, Guo D, Hu X, Xie L, Li B, Li Y, Lin T, Liu F, Liu Z, Lyu L, Mei Q, Shao J, Xin H, Yang F, Yang H, Yang W, Yao X, Yu C, Zhan S, Zhang G, Wang M, Zhu Z, Zhou B, Gu J, Xian M, Lyu Y, Li Z, Zheng H, Cui C, Deng S, Huang C, Li L, Liu P, Men P, Shao C, Wang S, Ma X, Wang Q, Zhai S. Li X, et al. Among authors: shao j. Front Pharmacol. 2022 Mar 28;13:845689. doi: 10.3389/fphar.2022.845689. eCollection 2022. Front Pharmacol. 2022. PMID: 35418863 Free PMC article.
COVID-19 Rebound After VV116 vs Nirmatrelvir-Ritonavir Treatment: A Randomized Clinical Trial.
Yang Z, Xu Y, Zheng R, Ye L, Lv G, Cao Z, Han R, Li M, Zhu Y, Cao Q, Ding Y, Wang J, Tan Y, Liu F, Wei D, Tan W, Jiang W, Sun J, Sun S, Shao J, Deng Y, Gao W, Wang W, Zhao R, Qiu L, Chen E, Zhang X, Wang S, Ning G, Xu Y, Bi Y. Yang Z, et al. Among authors: shao j. JAMA Netw Open. 2024 Mar 4;7(3):e241765. doi: 10.1001/jamanetworkopen.2024.1765. JAMA Netw Open. 2024. PMID: 38477921 Free PMC article. Clinical Trial.
RESULTS: The full analysis set included 345 participants (mean [SD] age, 53.2 [16.8] years; 175 [50.7%] were men) who received VV116 (n = 165) or nirmatrelvir-ritonavir (n = 180). ...
RESULTS: The full analysis set included 345 participants (mean [SD] age, 53.2 [16.8] years; 175 [50.7%] were men) who received VV116 …
Global burden and inequality of iron deficiency: findings from the Global Burden of Disease datasets 1990-2017.
Wang M, Gao H, Wang J, Cao C, Ying X, Wei Y, Yu Z, Shao J, Dong H, Yang M. Wang M, et al. Among authors: shao j. Nutr J. 2022 Mar 18;21(1):16. doi: 10.1186/s12937-022-00771-3. Nutr J. 2022. PMID: 35303854 Free PMC article.

RESULTS: A downward trend of global ID burden (from 569.3 (95% Uncertainty Interval [UI]: 387.8-815.6) to 403.0 (95% UI: 272.4-586.6), p < 0.001), age-adjusted DALYs per 100,000 population) but an uptrend of its inequalities (from 0.366 to 0.431, p < 0.001, Gini coefficient

…
RESULTS: A downward trend of global ID burden (from 569.3 (95% Uncertainty Interval [UI]: 387.8-815.6) to 403.0 (95% UI: 272.4-586.6), p < …
A Retrospective Study of Lenvatinib Monotherapy or Combined With Programmed Cell Death Protein 1 Antibody in the Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma in China.
Zhu S, Liu C, Dong Y, Shao J, Liu B, Shen J. Zhu S, et al. Among authors: shao j. Front Oncol. 2021 Dec 17;11:788635. doi: 10.3389/fonc.2021.788635. eCollection 2021. Front Oncol. 2021. PMID: 34976828 Free PMC article.
To assess the effectiveness and security of Lenvatinib in the Chinese population in a real-world setting, we enrolled 48 patients with unresectable liver cancer, managed from December 2018 to March 2021. Among them, 9 and 39 (83.30% men) patients had intrahepatic cholangio …
To assess the effectiveness and security of Lenvatinib in the Chinese population in a real-world setting, we enrolled 48 patients with unres …
Reduced Puncture Time and Radiation Exposure of Percutaneous Transpedicular Puncture with Electronic Conductivity Device: A Randomized Clinical Trial.
Zhai X, Li B, Yang Y, Shao J, Zhang Y, Hu W, Chen K, Yang M, Zhou X, Wei X, Chen Z, Zhao Y, Chen K, Bai Y, Li M. Zhai X, et al. Among authors: shao j. World Neurosurg. 2020 Mar;135:e43-e49. doi: 10.1016/j.wneu.2019.10.129. Epub 2019 Oct 31. World Neurosurg. 2020. PMID: 31678438 Clinical Trial.
Medical records of patients with vertebral compression fractures (VCFs) for bilateral PKP or PVP were collected, and each side was performed randomly with ECD or conventional trocar. RESULTS: We enrolled 61 patients (44 women, 17 men) with 75 vertebras with VCF. Compared w …
Medical records of patients with vertebral compression fractures (VCFs) for bilateral PKP or PVP were collected, and each side was performed …